$NRXP News
Last published 18h ago
- 18h agoNRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate UpdateGlobeNewswireWILMINGTON, Del., Nov. 12, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target depression, PTSD and suicidality, today announced that it will release its third quarter 2026 financial results before the market opens on Tuesday, November 17, 2026 via press release, which will be available o ...
- 2d agoNRXPNRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running ShortageGlobeNewswireWILMINGTON, Del., Nov. 11, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target depression, PTSD and suicidality, today announced that it commenced selling its newly approved preservative-free ketamine providing a guaranteed, U.S.-manufactured supply of a drug listed as in shortage since 2 ...
- 2w agoNRXPNRx Pharmaceuticals Investor Call - NRX PHARMACEUTICALS INCEarnings Call TranscriptsGood morning, ladies and gentlemen, and welcome to the NRX Pharmaceuticals Conference Call to discuss the FDA approval of preservative-free catamine. At this time, all lines are in listen-only mode. Following the present
- 2w agoNRXPNRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal DateGlobeNewswirePreservative-Free Ketamine is an American-manufactured presentation of ketamine that contains no benzethonium chloride (BZT), a toxic antimicrobial preservative that is not Generally Recognized as Safe (GRAS) by the
- 2w agoNRXPNRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free KetamineGlobeNewswireWILMINGTON, Del., Oct. 29, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP, "NRx" or "the Company")), a clinical-stage biopharmaceutical company developing therapeutics based on its
- 3w agoNRXPNRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free KetamineGlobeNewswireIn advance of November 10, 2026 GDUFA goal date, three commercial lots of Preservative-Free Ketamine have been successfully manufactured in compliance with "Process Validation" required under FDA "Good
- 4w agoNRXPNRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free KetamineGlobeNewswireIn advance of November 10, 2026, GDUFA goal date, all requested changes were classified as "MINOR."NRx was requested to prepare and submit labels with the proprietary name currently under review by FDA.NRx is
- 1mo agoNRXPNRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free KetamineGlobeNewswireAbbreviated New Drug Application (ANDA) Amendment related to the drug vial for preservative-free ketamine has been reclassified from a Major Amendment to a Minor Amendment.FDA has revised the Generic Drugs User Fee Act
- 2mo agoNRXPGeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)GlobeNewswireInvention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein (K Env), already coded in the "dark genome" of all people. K Env is found in
- 2mo agoNRXPDISRUPTIVE GROWTH CONFERENCE - NRX PHARMACEUTICALS INCEarnings Call TranscriptsAll good. All right. Quick reminder for everyone. And if you wanted to meet with Yoram, when we finish a session, ride out this door to the left. And the second door is where track one, one-on-one Q&A. So if you want to
- 2mo agoNRXPNRx Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireWILMINGTON, Del., Sept. 08, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that
- 2mo agoNRXPNRx Pharmaceuticals Q2 2026 Earnings Call - NRX PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon, ladies and gentlemen, and welcome to the NRX Pharmaceuticals Second Quarter 2026 Results Conference Call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a q
- 2mo agoNRXPNRx Pharmaceuticals Q2 2026 Earnings Call - NRX PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon, ladies and gentlemen, and welcome to the NRX Pharmaceuticals Second Quarter 2026 Results Conference Call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a q
- 2mo agoNRXPNRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ETGlobeNewswireKey recent and second quarter highlights include: Completed first-cycle FDA review of the Company’s ANDA for preservative-free ketamine with no drug-related major deficiencies. The sole remaining item, a
- 3mo agoNRXPNRx Pharmaceuticals Discusses FDA First Cycle Review - NRX PHARMACEUTICALS INCEarnings Call TranscriptsGood morning, ladies and gentlemen, and welcome to the NRX Pharmaceuticals Discusses FDA First Cycle Review Conference Call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct
- 3mo agoNRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial PlansGlobeNewswireMIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a
- 3mo agoNRXPFDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for ApprovalGlobeNewswireFDA identified no major deficiencies related to the ketamine drug product, ingredients, proposed labeling, CMC, or other drug-related review matters.Remaining item relates to manufacturer certification for a luer lock
- 4mo agoNRXPNRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation SystemGlobeNewswireFirst Zeta-navigated TMS treatments have begun at HOPE Therapeutics clinics in West Palm Beach and Sarasota, Florida, marking the transition from research deployment to active patient careAI-powered, sub-millimetric
- 4mo agoNRXPKadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with AcquisitionBusiness WireComplaint filed in San Diego County Superior Court seeks specific performance, alleging NRx warranted it had funds to close while concealing it lacked committed financing for the transaction. Kadima Neuropsychiatry
- 4mo agoNRXPZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE TherapeuticsPR NewswireZETA SURGICAL and HOPE Therapeutics, an NRx Pharmaceuticals company (Nasdaq: NRXP), today announced the first patient treatment with the FDA-cleared...
- 4mo agoNRXPNRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of DepressionGlobeNewswireD-Cycloserine (DCS) has been reported to augment the effect of Transcranial Magnetic Stimulation (TMS) in remission from depression and suicidality in several published clinical studies.NRx Pharmaceuticals is developing
- 5mo agoNRXPNRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.GlobeNewswireOsmind presented a retrospective comparative study of de-identified electronic health record data in a sample of 8,224 patients with treatment resistant depression treated with IV ketamine and 1,830 patients treated with
- 5mo agoNRXPNRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters' OptionGlobeNewswireWILMINGTON, Del., June 04, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced the closing of its
- 5mo agoNRXPNRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common StockGlobeNewswireWILMINGTON, Del., June 03, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced the pricing of an
- 5mo agoNRXPNRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common StockGlobeNewswireWILMINGTON, Del., June 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it intends to offer
- 5mo agoNRXPNRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026GlobeNewswireEMOCARE is a smartphone-based passive monitoring tool that generates a continuous, real-time measure of depression from patient voice, facial expression, motion, and screen behavior, and is the first passive monitoring
- 5mo agoNRXPNRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation SystemGlobeNewswireDeployment at HOPE's West Palm Beach clinic brings AI-powered, sub-millimetric image guidance to the delivery of Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and other
- 5mo agoNRXPNRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireKey highlights from the first quarter of operations under the expanded management team include the following: Anticipated FDA decision on the Company's ANDA for Preservative-Free Ketamine in Q3 2026, with favorable
- 6mo agoNRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate UpdateGlobeNewswireWILMINGTON, Del., May 14, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its
- 6mo agoNRXPNRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and SuicidalityGlobeNewswirePreliminary research suggests that D-cycloserine significantly enhances the effect of Transcranial Magnetic Stimulation (TMS) Trial is planned to be conducted at a leading US academic teaching hospital, three HOPE
- 6mo agoNRXPNRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free KetamineGlobeNewswireBased on FDA Office of Generic Drugs guidance previously announced, NRx has transmitted an initial GMP manufacturing order to its US-based manufacturer.NRx has completed confirmatory GMP audits of manufacture and is
- 6mo agoNRXPNRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine ProgramGlobeNewswireNRx has received a positive review letter (Discipline Review Letter) addressing Drug Quality requesting only "Minor" administrative changesNRx conducted a meeting with leadership of the FDA Office of Generic Drugs in
- 6mo agoNRXPNRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and SuicidalityGlobeNewswirePresident Trump signed an Executive Order: ACCELERATING MEDICAL TREATMENTS FOR SERIOUS MENTAL ILLNESS on April 18, 2026.The order directs acceleration of research and lowered barriers to approvals of psychedelic
- 7mo agoNRXPNRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder ApplicationsGlobeNewswireDr. Dennis K. McBride, PhD (CAPT, Medical Service Corps, US Navy, Ret., Distinguished Research Fellow, National Defense University, and former senior executive, Office Secretary of Defense) to serve as first President of
- 7mo agoNRXPNRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company's first Chief Commercial OfficerGlobeNewswireMr Tyson has both clinical experience treating patients with serious mental health disorders and 25 years of successful industry commercial experience in the development and sales of medications in this fieldMr. Tyson is
- 7mo agoNRXPNRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx's Preservative-Free Ketamine ApplicationGlobeNewswireNRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for NRx's preservative-free ketamine product. Labeling remains subject to final supervisory review.NRx
- 7mo agoNRXPHope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered "Depression Thermometer" Across its Interventional Psychiatry NetworkGlobeNewswireHope Therapeutics ((subsidiary of NRx Pharmaceuticals, NASDAQ:NRXP) partners with Emobot Health to deploy its AI-powered "Depression Thermometer" across its interventional psychiatry clinic network.Emobot's
- 7mo agoNRXPNRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial ProgressGlobeNewswireKey highlights for the first full year of operation under the new management team include: A year-over-year reduction in operating expenses with $7.8 Million cash on hand at year end. With ongoing revenue from
- 8mo agoNRXPNRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA MeetingGlobeNewswireNRx has received confirmatory FDA minutes from in-person Type C meeting attended by leadership of FDA Division of Psychiatry, FDA Office of Neuroscience, and FDA Center for Drug Evaluation and Research.Minutes are
- 8mo agoNRXPHOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSDGlobeNewswirePublished results have shown 87% clinical response to non-invasive Transcranial Magnetic Stimulation with neuroplastic medications.Clinical leadership by physicians trained at Harvard, Johns Hopkins, Georgetown, and
- 8mo agoNRXPNRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation OfficerGlobeNewswireProf. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication
- 8mo agoNRXPNRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA MeetingGlobeNewswireNRx together with Osmind, Inc. conducted an in-person meeting attended by leadership of the FDA Division of Psychiatry Products and leadership of the FDA Center for Drug Evaluation and Research (CDER)Oral guidance
- 10mo agoNRXPNRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record DateGlobeNewswireWILMINGTON, Del., Jan. 16, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) (the "Company"), a clinical-stage biopharmaceutical company, today announced that it will hold its annual meeting of
- 10mo agoNRXPNRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 ApprovalGlobeNewswireNRX-100 (preservative-free ketamine) has been granted Fast Track Designation by FDA for treatment of suicidal ideation in patients with Depression and Bipolar Depression.Real-world evidence, consistent with FDA guidance,
- 10mo agoNRXPNRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictionsGlobeNewswireProgram will integrate existing neurocare clinics with HOPE Therapeutics clinics and will engage the already-installed base of 400+ Apollo® Transcranial Magnetic Stimulation (TMS) machines nationwide.Program will
- 11mo agoNRXPNRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversionGlobeNewswireRemaining $5.4 million debt was repaid through strategic equity conversion in common stock with no additional warrants or adjustment provisionsCompany anticipates that Dec 31 balance sheet will reflect no outstanding
- 11mo agoNRXPNRx Pharma - NobleCon21 Presentation - NRX PHARMACEUTICALS INCEarnings Call TranscriptsSo, thank you. Thank you all for coming at the end of the day. And I'd really like to give you an update on where we are with NRX and some things that have happened recently that are you know even surprising to us and yo
- 11mo agoNRXPNRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic StimulationGlobeNewswireAs previously announced, low dose D-cycloserine has been associated with augmentation of the antidepressant and antisuicidal response achieved by Transcranial Magnetic Stimulation (TMS).NRx has amended its
- 11mo agoNRXPNRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV KetamineGlobeNewswireFDA has determined that NRx's Abbreviated New Drug Application (ANDA) is "substantially complete" and received for review. Assigned GDUFA goal date is July 29, 2026.NRx has applied to FDA for use of KETAFREE™ as a
- 11mo agoNRXPNRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update CallGlobeNewswireWILMINGTON, Del., Dec. 02, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it